0
Inquiry Basket
Quote

Resources

ivig

Beyond Pegloticase: Next-Generation Uricase Therapies and the Future of Gout Treatment

Future Outlook • April 2026 • Advanced Therapeutics Research Group

ivig

Clinical Evidence Review of Pegloticase in Refractory Gout

Clinical Evidence Review • April, 2026 • Clinical Research Team

ivig

From Uric Acid to Allantoin: The Biochemical Pathway Restored by Recombinant Uricase

White Paper • April, 2026 • Biochemical Pathway Research Group

ivig

Gout Biologics Trend Review

Trend Report • April, 2026 • Market & Pipeline Intelligence Group

ivig

Hyperuricemia Animal Model Protocol

Technical Protocol • April, 2026 • Preclinical Research Division

ivig

Immunogenicity Challenges in Pegloticase Therapy

White Paper • April, 2026 • Immunology Research Group

ivig

Mechanism Comparison of Uricase and Xanthine Oxidase Inhibitors

Mechanism Comparison Article • April, 2026 • Translational Science Group

ivig

Mechanism of Pegloticase

Mechanism Explainer • April, 2026 • Biopharmaceutical Research Group

ivig

Pegloticase FAQ

FAQ • April, 2026 • Medical Information Team

ivig

PEGylation Technology in Biopharmaceutical Development

White Paper • April, 2026 • Biopharmaceutical Research Group

ivig

PK Study Design for Pegloticase and PEGylated Enzymes

PK Study Design • April, 2026 • Pharmacokinetics Research Team

ivig

Recombinant Uricase Production Overview

Production Article • April, 2026 • Bioprocess Development Group

ivig

Uricase Activity Assay Protocol

Protocol Guide • April, 2026 • Bioassay Development Team

ivig

Uricase Therapy Review

Review Article • April 2026 • Therapeutic Review Board

ivig

Imiglucerase and Enzyme Replacement Therapy for Gaucher Disease

White Paper • March 2026 • Therapeutic Enzyme Research Group

ivig

A Review of Recombinant β-Glucocerebrosidase in Biomedical Research

Technical Review • March 2026 • Enzyme Therapeutics Division

ivig

Protocol: Evaluating Imiglucerase Activity in Gaucher Disease Cell Models

Research Protocol • March, 2026 • Lysosomal Storage Disorders Research Group

ivig

Application of Imiglucerase in Lysosomal Storage Disease Research

Application Note • March, 2026 • Therapeutic Proteins Research Group

ivig

How Imiglucerase Restores Lysosomal Function in Gaucher Disease

Mechanism Insight Article • March, 2026 • Therapeutic Enzyme Research Group

ivig

Methods for Measuring β-Glucocerebrosidase Activity in Biological Samples

Technical Guide • March, 2026 • Biochemical Research Group

ivig

Gaucher Disease: Molecular Basis and Research Models

Disease Resource • March 2026 • Therapeutic Research Group

ivig

Comparison of Enzyme Replacement Therapies for Gaucher Disease

Comparative Analysis • March, 2026 • Therapeutic Proteins Research

ivig

Designing Experiments Using Recombinant Imiglucerase in Disease Models

Technical Guide • March, 2026 • Therapeutic Research Group

ivig

The Glucocerebrosidase Pathway and Its Role in Lipid Metabolism

Pathway Analysis • March 2026 • Lysosomal Biology Research Group

ivig

Frequently Asked Questions About Imiglucerase in Research

Technical FAQ • March 2026 • Technical Support Team

ivig

Recombinant Enzyme Technology in Lysosomal Disease Research

Technology Overview • March 2026 • Bioprocessing Research Division

ivig

IVIg in Neurodegenerative Research: Analyzing the Clinical Trials for Alzheimer's Disease

Research Perspective • February, 2026 • Neurodegenerative Research Group

ivig

Assay Development: Validating IVIg Batches for HAMA Interference in Sandwich ELISA

Protocol Guide • February, 2026 • Analytical Development Group

ivig

Beyond Plasma: Are Recombinant Fc Fragments and Fc-Mimetics the Future of IVIg Therapy?

Therapeutic Analysis • February, 2026 • Biopharmaceutical Research Group

ivig

Generations of IVIg: A Review of Manufacturing Safety Steps from 1980s to Present

Review Article • February, 2026 • Biopharmaceutical Research Group

ivig

Production Process Comparison of Research-Grade IVIg

White Paper • January 10, 2026 • Biopharmaceutical Research Group

ivig

Lyophilized vs. Liquid IVIg: Stability Profiles and Storage Best Practices for Laboratories

Technical Guide • January 2026 • Biopharmaceutical Research Group

ivig

SOP-IVIg-FC: Universal Fc Blocking Protocol for Flow Cytometry

Standard Operating Procedure • January, 2026 • Flow Cytometry Core Facility

ivig

Protocol: Therapeutic Evaluation of IVIg in Passive Murine Models of Immune Thrombocytopenia (ITP)

Technical Protocol • January 2026 • Biopharmaceutical Research Group

ivig

Optimizing Flow Cytometry: Using IVIg as a Universal Fc Blocking Agent to Reduce Background Noise

Technical Article • January 2026 • Biopharmaceutical Research Group

ivig

Understanding IgG Subclass Distribution in IVIg and Its Impact on Experimental Design

Technical Documentation • January 23, 2026 • Immunology Research Group

Online Inquiry

  • Size: 100ug 500ug 1mg 5mg 10mg 100mg 500mg 1g
  • Conjugation: None R-PE APC Biotin FITC Alexa Flour Others
CONTACT US

For more information on how our products could help advance your project, please contact us.

Contact Us

ENTER YOUR EMAIL HERE TO SUBSCRIBE.

Copyright © 2026 Creative BioMart. All Rights Reserved.